BridgeBio Pharma Files Proxy Materials
Ticker: BBIO · Form: DEFA14A · Filed: May 9, 2025 · CIK: 1743881
| Field | Detail |
|---|---|
| Company | Bridgebio Pharma, Inc. (BBIO) |
| Form Type | DEFA14A |
| Filed Date | May 9, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, sec-filing, corporate-governance
TL;DR
BridgeBio filed proxy docs, no fee. Standard shareholder stuff.
AI Summary
BridgeBio Pharma, Inc. filed a Definitive Additional Materials (DEFA14A) on May 9, 2025. This filing is related to their proxy statement and does not involve a fee. The company is incorporated in Delaware and its fiscal year ends on December 31st.
Why It Matters
This filing indicates ongoing corporate governance and shareholder communication activities for BridgeBio Pharma, Inc., which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — This is a routine SEC filing (DEFA14A) for proxy materials, indicating standard corporate operations rather than a significant event.
Key Players & Entities
- BridgeBio Pharma, Inc. (company) — Registrant
- 0001140361-25-018190 (filing_id) — Accession Number
- 20250509 (date) — Filing Date
- 001-38959 (company_id) — SEC File Number
FAQ
What type of SEC filing is this?
This is a DEFA14A filing, specifically marked as Definitive Additional Materials.
Who is the filing company?
The filing company is BridgeBio Pharma, Inc.
When was this filing made?
The filing was made on May 9, 2025.
Is there a fee associated with this filing?
No fee is required for this filing.
What is the company's standard industrial classification?
The company's Standard Industrial Classification is Pharmaceutical Preparations [2834].
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on May 9, 2025 regarding BridgeBio Pharma, Inc. (BBIO).